Robert Chan, MD
Urogynecology and Reconstructive Pelvic Surgery · Greenbrae, CANPI 1295980647
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Coloplast at 45.4% of the total. Reporting peaked in 2019 at $7,427 and has fallen 85.8% since, to $1,053 in 2025.
Across 222 payments — averaging $62.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$6K
- Axonics, Inc.$1K
- Sumitomo Pharma America, Inc.$954
- Boston Scientific$859
- AbbVie$747
- Neotract Inc.$719
- plus $3K from 35 others
What the payments were for
- Travel & lodging$1,2479%
- Food & beverage$6,36446%
- Education$6,13545%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 11 | $6,258 |
| Axonics, Inc. | 16 | $1,136 |
| Sumitomo Pharma America, Inc. | 31 | $954 |
| Boston Scientific | 15 | $859 |
| AbbVie(2 entities) | 36 | $747 |
| Neotract Inc. | 10 | $719 |
| Johnson & Johnson(2 entities) | 11 | $448 |
| Astellas Pharma US Inc | 22 | $417 |
| Laborie Medical Technologies Corp. | 3 | $180 |
| Pfizer | 7 | $171 |
| C. R. Bard, Inc. & Subsidiaries | 6 | $166 |
| Dornier Medtech America, Inc | 1 | $145 |
| Ambu Inc. | 4 | $143 |
| Astellas Pharma Global Development | 1 | $130 |
| Endo Pharmaceuticals Inc. | 7 | $128 |
| Ferring Pharmaceuticals Inc. | 1 | $125 |
| EDAP Technomed Inc | 1 | $100 |
| Rochester Medical Corporation | 4 | $84 |
| Telix Pharmaceuticals | 3 | $77 |
| Olympus America Inc. | 2 | $77 |
| BD | 3 | $71 |
| Biotissue Holdings Inc. | 2 | $66 |
| Smith+Nephew | 2 | $63 |
| Blue Earth Diagnostics | 3 | $55 |
| Urogen Pharma, Inc. | 3 | $53 |
| Endo USA, Inc. | 2 | $41 |
| Davol Inc. | 1 | $38 |
| Tolmar, Inc. | 1 | $30 |
| Convatec Inc. | 1 | $30 |
| Caldera Medical, Inc | 1 | $28 |
| 180 Medical, Inc. | 1 | $25 |
| Vertex | 1 | $25 |
| Therapeuticsmd, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $23 |
| Teleflex LLC | 1 | $21 |
| Abbott | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Dentsply IH AB | 1 | $18 |
| Sagent Pharmaceuticals | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$5,950
- Axonics$661
- Bulkamid$546
- UroLift$447
- AMS$375
- Dornier MedTech$145
- XTANDI$130
- ADSTILADRIN$125
- Optilume BPH Drug Coated Balloon Catheter$121
- GREENLIGHT$115
- rezum Generator$108
- STRATAFIX$102
- VISTASEAL$102
How this compares
$13,772 in reported general payments places this provider in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 49 | $53,032 |
| GemtesaVibegron | 58 | $48,726 |
| Methenamine Hippurate | 73 | $8,759 |
| Tamsulosin Hcl | 416 | $7,112 |
| Oxybutynin Chloride ErOxybutynin Chloride | 102 | $3,156 |
| Finasteride | 115 | $1,969 |
| Estradiol | 24 | $1,700 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 89 | $1,530 |
| Testosterone Cypionate | 21 | $1,257 |
| Cephalexin | 51 | $689 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $516 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 129 | $490 |
| Desmopressin Acetate | 12 | $475 |
| Ciprofloxacin Hcl | 60 | $248 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $417 | $53,03249 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $954 | $48,72658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Greenbrae
- Sujatha PathiGreenbrae$6K
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.